How we work with our VC and investor clients
InSymbiosis offers VCs and investors an alternative strategy for the development of their drug assets. Historically, investors have invested in expensive biotech company infrastructure and senior “C” level managers whilst the assets they are developing are relatively early stage and have not yet attained proof of concept. When you multiply these expenses across multiple assets and companies, the cost of just the infrastructure and “C” level management is extremely high. InSymbiosis provides investors with an alternative option where their investments in infrastructure can be minimized since InSymbiosis can provide all of the infrastructure, knowledge, quality management tools, regulatory expertise and project management resources required to transition drug assets from the preclinical stage through to Phase II human proof of concept. The result is a significant reduction in the overall cost which lowers the risk of drug development and allows the money saved to be redirected to other drug development programs.